NRIX
Nurix TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
The bull case is that Nurix now has a clearer registrational path around bexobrutideg, with an ongoing pivotal Phase 2 study designed to support potential Accelerated Approval and a planned confirmatory Phase 3 start by mid-2026, while the balance sheet still showed $540.7 million at February 28, 2026 [#8-K-2026-04-08] [#10-Q-2026-04-08].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.8.
What can break
Execution risk around enrollment, data quality, and timing is significant for a company whose equity story is concentrated in bexobrutideg milestones and partner-program progress.
Momentum
73
Value
41
Sentiment
66
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $18.00 · Bull $26.00 · Bear $10.00
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-05 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $30.00
Why
Momentum73 · Δ7d -1.8
Value41 · Δ7d +0.0
Sentiment66 · Δ7d +7.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
73
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.8
Δ21d
+15.2
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
66
33% active weight
Current posture
7d trendImproving
Δ7d
+7.2
Δ21d
+4.4
Why this grade
Composite grade B. Momentum 73.4 / Value 41.1 / Sentiment 65.8
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.69B
Beta
1.96
Shares Out
101.36M
P/E (TTM) · Derived
-5.5
P/S (TTM)
21.18
P/FCF (TTM) · Derived
-5.71
Rev YoY
-37.3%
EPS YoY
-52.7%
Gross Margin
-
Op Margin
-319.3%
Net Debt
-$609.58M
Current Ratio
5.35
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology